Egyptian International Pharmaceutical Industries Company (EGX:PHAR)
Egypt
· Delayed Price · Currency is EGP 51.03
+1.92 (3.91%)
At close: Jun 25, 2025
EGX:PHAR Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 8,387 | 7,591 | 5,232 | 3,955 | 3,409 | 2,886 | Upgrade
| |
Revenue Growth (YoY) | 46.06% | 45.09% | 32.27% | 16.03% | 18.13% | -15.40% | Upgrade
|
Cost of Revenue | 4,654 | 4,244 | 2,983 | 2,397 | 1,957 | 1,675 | Upgrade
|
Gross Profit | 3,733 | 3,346 | 2,248 | 1,558 | 1,452 | 1,211 | Upgrade
|
Selling, General & Admin | 1,096 | 1,065 | 788.09 | 683.2 | 566.08 | 547.58 | Upgrade
|
Research & Development | 64.68 | 70.45 | 43.23 | 43.68 | 34.96 | 20.87 | Upgrade
|
Other Operating Expenses | 323.67 | 378.57 | 167.2 | 134.35 | 60.79 | 55.35 | Upgrade
|
Operating Expenses | 1,790 | 1,844 | 1,038 | 896.23 | 674.83 | 623.8 | Upgrade
|
Operating Income | 1,944 | 1,503 | 1,211 | 662 | 776.85 | 587.32 | Upgrade
|
Interest Expense | -1,124 | -928.54 | -388.52 | -195.42 | -136.25 | -83.16 | Upgrade
|
Interest & Investment Income | 105.7 | 72.05 | 26.24 | 57.77 | 32.11 | 40.57 | Upgrade
|
Earnings From Equity Investments | 151.58 | 151.58 | 74.51 | - | - | 37.18 | Upgrade
|
Currency Exchange Gain (Loss) | 157.21 | 699.88 | 139.63 | 286.4 | -6.25 | -11.55 | Upgrade
|
Other Non Operating Income (Expenses) | 20.04 | 11.04 | 1.51 | -20.62 | -24.04 | 13.37 | Upgrade
|
EBT Excluding Unusual Items | 1,254 | 1,509 | 1,064 | 790.13 | 642.41 | 583.74 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.9 | 0.22 | 4.69 | 3.7 | 2.78 | 3.8 | Upgrade
|
Pretax Income | 1,255 | 1,509 | 1,069 | 793.83 | 645.19 | 587.55 | Upgrade
|
Income Tax Expense | 443.16 | 411.83 | 245.62 | 150.07 | 156.9 | 100.15 | Upgrade
|
Earnings From Continuing Operations | 812.04 | 1,097 | 823.31 | 643.76 | 488.29 | 487.4 | Upgrade
|
Minority Interest in Earnings | -1.1 | -1.21 | -0.99 | -0.78 | -0.53 | -0.89 | Upgrade
|
Net Income | 810.95 | 1,096 | 822.32 | 642.98 | 487.75 | 486.51 | Upgrade
|
Net Income to Common | 810.95 | 1,096 | 822.32 | 642.98 | 487.75 | 486.51 | Upgrade
|
Net Income Growth | -34.46% | 33.25% | 27.89% | 31.83% | 0.25% | -27.45% | Upgrade
|
Shares Outstanding (Basic) | 149 | 149 | 149 | 99 | 99 | 98 | Upgrade
|
Shares Outstanding (Diluted) | 149 | 149 | 149 | 99 | 99 | 98 | Upgrade
|
Shares Change (YoY) | - | - | 50.00% | - | 1.64% | -1.61% | Upgrade
|
EPS (Basic) | 5.45 | 7.37 | 5.53 | 6.48 | 4.92 | 4.99 | Upgrade
|
EPS (Diluted) | 5.45 | 7.37 | 5.53 | 6.48 | 4.92 | 4.99 | Upgrade
|
EPS Growth | -34.46% | 33.25% | -14.74% | 31.83% | -1.36% | -26.26% | Upgrade
|
Free Cash Flow | -1,894 | -4,121 | -2,198 | -859.77 | -53.27 | -38.7 | Upgrade
|
Free Cash Flow Per Share | -12.73 | -27.70 | -14.77 | -8.67 | -0.54 | -0.40 | Upgrade
|
Dividend Per Share | 1.500 | 1.500 | 1.000 | 1.000 | 1.500 | - | Upgrade
|
Dividend Growth | 50.00% | 50.00% | - | -33.33% | - | - | Upgrade
|
Gross Margin | 44.51% | 44.09% | 42.98% | 39.40% | 42.59% | 41.97% | Upgrade
|
Operating Margin | 23.18% | 19.79% | 23.14% | 16.74% | 22.79% | 20.35% | Upgrade
|
Profit Margin | 9.67% | 14.44% | 15.72% | 16.26% | 14.31% | 16.86% | Upgrade
|
Free Cash Flow Margin | -22.58% | -54.29% | -42.01% | -21.74% | -1.56% | -1.34% | Upgrade
|
EBITDA | 2,040 | 1,599 | 1,314 | 759.39 | 867.73 | 726.89 | Upgrade
|
EBITDA Margin | 24.32% | 21.07% | 25.12% | 19.20% | 25.46% | 25.19% | Upgrade
|
D&A For EBITDA | 96.24 | 96.53 | 103.17 | 97.39 | 90.88 | 139.57 | Upgrade
|
EBIT | 1,944 | 1,503 | 1,211 | 662 | 776.85 | 587.32 | Upgrade
|
EBIT Margin | 23.18% | 19.79% | 23.14% | 16.74% | 22.79% | 20.35% | Upgrade
|
Effective Tax Rate | 35.31% | 27.30% | 22.98% | 18.90% | 24.32% | 17.04% | Upgrade
|
Updated Mar 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.